Gee...What's Causing that Pap? - Slides

Update Item Information
Identifier walsh_2018_s1_c3-2
Title Gee...What's Causing that Pap? - Slides
Creator Susan Mollan; Daniel White; Santhosh Nagaraju; Swarupsinh Chavda; Tom Hayton; Saiju Jacob
Affiliation (SM) Birmingham Neuro-Ophthalmology, Queen Elizabeth Hospital, Birmingham, United Kingdom; (DW) (SN) (SC (TH)( SJ) University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Subject Papilledema; Meningo-Encephalitis; Vision Loss
History A 36 year old woman presented with history of Myasthenia Gravis (MG) since the age of 18. She was known to have dry eyes and hypothyroidism. Past surgical history included a thymectomy (age 23 years). The MG had been difficult to control with past medications including corticosteroids, azathioprine, methotrexate and mycophenolate. Eighteen months prior to this presentation she was enrolled in a double blind placebo controlled trial with Eculizumab, a terminal complement inhibitor. She had required intravenous immunoglobin (IV IG) as rescue therapy initially and went on to open label Eculizumab 9 months prior to this admission. She had subsequently developed Alopecia areata (no family history), followed by nummular dermatitis, and then Alopecia totalis. The decision was made to have a drug holiday. This precipitated a worsening of the MG requiring IV IG. She restarted Eculizumab and 3 weeks later developed swinging fevers, nausea and vomiting and generalised polyarthralgia. On admission her vision (6/5 OU) and colour vision were normal. She had longstanding symptomatic left limitation of abduction, with normal saccades. She had no relative afferent pupillary defect and enlarged blind spots on Humphrey visual field testing. Dilated examination showed bilateral papilloedema. There was no other cranial neuropathy. Blood tests on admission were normal, including inflammatory markers and three sets of blood cultures with no growth. Inflammatory antibody tests were normal, as was HIV and testing for Tuberculosis. Lumbar puncture opening pressure was 23 cm CSF, with raised protein (0.93g/dl), low CSF glucose compared to serum, a mononuclear pattern, oligoclonal bands in the CSF only and PCR for viral and bacterial factors were negative. Initial MRI imaging was normal. CT thorax, abdomen and pelvis was normal. FDG-PET imaging showed increased uptake along the spinal cord. Bone marrow biopsy was normal. A brain biopsy and one further diagnostic test was performed.
Disease/Diagnosis Autoimmune Glial Fibrillary Acidic Protein (GFAP) Astrocytopathy
Presenting Symptom A 36 year old woman presented with history of Myasthenia Gravis (MG) since the age of 18. She was known to have dry eyes and hypothyroidism. Past surgical history included a thymectomy (age 23 years). The MG had been difficult to control with past medications including corticosteroids, azathioprine, methotrexate and mycophenolate. Eighteen months prior to this presentation she was enrolled in a double blind placebo controlled trial with Eculizumab, a terminal complement inhibitor. She had required intravenous immunoglobin (IV IG) as rescue therapy initially and went on to open label Eculizumab 9 months prior to this admission. She had subsequently developed Alopecia areata (no family history), followed by nummular dermatitis, and then Alopecia totalis. The decision was made to have a drug holiday. This precipitated a worsening of the MG requiring IV IG. She restarted Eculizumab and 3 weeks later developed swinging fevers, nausea and vomiting and generalised polyarthralgia. On admission her vision (6/5 OU) and colour vision were normal. She had longstanding symptomatic left limitation of abduction, with normal saccades. She had no relative afferent pupillary defect and enlarged blind spots on Humphrey visual field testing. Dilated examination showed bilateral papilloedema. There was no other cranial neuropathy. Blood tests on admission were normal, including inflammatory markers and three sets of blood cultures with no growth. Inflammatory antibody tests were normal, as was HIV and testing for Tuberculosis. Lumbar puncture opening pressure was 23 cm CSF, with raised protein (0.93g/dl), low CSF glucose compared to serum, a mononuclear pattern, oligoclonal bands in the CSF only and PCR for viral and bacterial factors were negative. Initial MRI imaging was normal. CT thorax, abdomen and pelvis was normal. FDG-PET imaging showed increased uptake along the spinal cord. Bone marrow biopsy was normal. A brain biopsy and one further diagnostic test was performed.
Date 2018-05
References 1 Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis JAMA Neurol, 73,1297-1307, 2016 2 Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, et al. Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients. Ann Neurol, 81, 298-309, 2017 3 Yang X, Liang J, Huang Q, Xu H, Gao C, et al. Treatment of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: Follow-Up in 7 Cases. Neuroimmunomodulation, 24, 113-119, 2017
Language eng
Format application/pdf
Format Creation Microsoft PowerPoint
Type Text
Source 2018 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting Frank B. Walsh Sessions; 2018
Collection Neuro-Ophthalmology Virtual Education Library: Walsh Session Annual Meeting Archives: https://novel.utah.edu/Walsh/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2018. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6x10bbv
Setname ehsl_novel_fbw
ID 1326572
Reference URL https://collections.lib.utah.edu/ark:/87278/s6x10bbv
Back to Search Results